SOSV is a global venture capital firm based in Princeton, New Jersey, founded in 1995. It specializes in early-stage investments, focusing on deep technology innovations that address human and planetary health. The firm operates startup development programs, notably HAX and IndieBio, which provide resources, facilities, and lab equipment to accelerate the growth of promising startups. SOSV supports companies from their inception through various funding stages, including seed and series A rounds, while offering ongoing assistance to help them scale and attract additional investors. By concentrating on revolutionary technologies and cross-border markets, particularly in Asia, SOSV aims to foster significant advancements that benefit humanity and the environment.
The National Science Foundation (NSF) is an independent federal agency established in 1950 and based in Alexandria, Virginia. It is dedicated to supporting research and education in science and engineering across a wide range of disciplines. The NSF provides significant non-dilutive funding, up to $1.5 million, to startups and small businesses through its America's Seed Fund initiative, which is part of the Small Business Innovation Research (SBIR) program mandated by Congress. With an operating budget of approximately $7.8 billion, the NSF is committed to advancing fundamental research and education, thus fostering innovation and technological development in the United States.
MedTech Innovator is the industry’s nonprofit global competition and accelerator for medical device, digital health and diagnostic companies. Our mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. MedTech Innovator annually features 100 companies that address one or more of the transformative themes identified in an annual survey of leading manufacturers and providers.
The European Innovation Council (EIC), established in 2020 and headquartered in Brussels, Belgium, is dedicated to supporting high-potential innovators, entrepreneurs, small enterprises, and researchers. Its primary focus is on fostering early-stage startups that demonstrate significant environmental, social, and governance (ESG) impacts. The EIC collaborates with private investors to co-invest in ventures, particularly within the deep technology sector, aiming to drive innovation and sustainable development across Europe. By providing financial backing and resources, the EIC seeks to enhance the growth potential of promising startups and contribute to a more innovative and competitive European economy.
The National Institutes of Health (NIH) is a leading biomedical research facility in the United States, operating under the Department of Health and Human Services. Established in 1887 and based in Bethesda, Maryland, NIH is the primary agency responsible for biomedical and health-related research in the country. It comprises 27 separate institutes and centers, each focusing on different disciplines within biomedical science. NIH conducts its own scientific research through the Intramural Research Program and provides significant funding for research at external institutions via the Extramural Research Program. With a workforce that includes 1,200 principal investigators and over 4,000 postdoctoral fellows, NIH has been instrumental in major medical breakthroughs, such as the development of vaccines for hepatitis and human papillomavirus, as well as the discovery of treatments for various health conditions. As the world's largest source of medical research funding, NIH continues to advance scientific knowledge and contribute to public health improvements.
Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, founded in 2006. With additional offices in Beijing, Suzhou, Hong Kong, and Singapore, the firm focuses on early to growth-stage investments across various sectors, including healthcare, information technology, consumer goods, mobile internet, artificial intelligence, and clean technology. Qiming Venture Partners has a strong track record, having invested in over 530 innovative companies, with more than 200 achieving successful exits through public offerings or mergers and acquisitions. The firm is recognized for its deep technical expertise and hands-on operational support, making it a preferred partner for CEOs and startups seeking to scale their operations. Its partners are often sought after as board members, reflecting their status as respected business leaders and thought leaders in the venture capital landscape.
MassChallenge is a global nonprofit startup accelerator headquartered in Boston, Massachusetts, founded in 2009. It supports early-stage entrepreneurs from various industries, including technology, healthcare, and finance, by providing mentorship, resources, and networking opportunities. With locations in countries such as Israel, Mexico, Switzerland, and Texas, MassChallenge operates a non-equity model, allowing startups to retain full ownership while benefiting from expert guidance and connections. The accelerator conducts various programs tailored to specific sectors, such as MassChallenge HealthTech and MassChallenge FinTech, which facilitate partnerships between startups and established enterprises to drive innovation and market growth. Through its extensive global network, MassChallenge aims to strengthen the innovation ecosystem and empower high-potential startups to create meaningful impact.
EASME is a European Union executive agency that supports small and medium-sized enterprises and promotes innovation in Europe. It manages projects in the areas of small and medium-sized enterprises, as well as the environment, energy, and maritime sectors, funded by COSME, LIFE, and EMFF. EASME organizes the European Sustainable Energy Week and serves industries such as environmental management, energy production, and maritime activities.
HAX is a venture capital program focused on accelerating hardware startups, operating from San Francisco and Shenzhen. Established in 2012, HAX provides founders with essential resources to rapidly prototype and iterate their products, encompassing physical models, technology developments, user interaction studies, and comprehensive business plans. The program supports accepted teams through a combination of full-time staff, mentors, and a vibrant startup community, emphasizing the development of scalable business strategies. Once products are ready for market introduction, teams transition to San Francisco, where HAX assists with business development, fundraising, and establishing critical partnerships. The program includes specialized initiatives such as HAX Growth, a 7-week bootcamp for launching B2C and B2B hardware startups, and HAX Boost, which helps teams refine their sales and marketing strategies while preparing for growth. HAX is part of SOSV, a global venture capital firm with a diverse portfolio, focusing on technology startups that aim to create meaningful innovations.
Venture Kick, a private philanthropic initiative, provides as much 150,000 Swiss francs in pre-seed funding to Swiss startups and offers structured, entrepreneurial training to build robust, winning businesses. Entrepreneurs pitch for finance as many as three times, as they compete for increasing amounts of funding at each stage. Founders gain direct feedback from the expert juries and access to an international network of successful entrepreneurs and investors. Venture Kick has supported 600 Swiss startup projects with 24.9 million francs to date. Supported projects have incorporated as 454 active companies, creating 6,033 jobs, and attracting 2.49 billion francs worth of subsequent investment. Companies founded by Venture Kick alums represented 55 percent of the TOP 100 Swiss Startup Award 2018. In 2019 Venture Kick will support idea-stage startup projects with 4.35 million francs, to bring Swiss science to global markets.
Bpifrance is a financial institution dedicated to supporting companies throughout their development stages, particularly those preparing for stock market listing and seeking credit equity. The organization provides a range of financial solutions, including financing, innovation assistance, and capital investment. By integrating various entities such as OSEO and CDC Entreprises, Bpifrance aims to deliver tailored financial support that addresses the specific needs of businesses. The institution is committed to fostering innovation and helping companies transition toward sustainable growth, ensuring they are well-equipped to face future challenges.
US Department of Energy is a government agency that regulates energy policy, research, and development. The Energy Department's mission is to ensure America’s security and prosperity by addressing its energy, environmental, and nuclear challenges through transformative science and technology solutions.
Innovate U.K. is a NPO that offers funding services to support science and technology innovations. The organization offers services and information on births, deaths, marriages, business, self-employed, childcare, parenting, citizenship, law, disabled persons, transportation, education, environment, housing, money, tax, travel, immigration, and jobs. Innovate U.K. is based in Swindon.
OrbiMed is a healthcare-focused investment firm based in New York City, established in 1989. The firm specializes in providing a range of financing solutions, including bridge loans, senior debt, and structured debt capital for both commercial-stage public and private healthcare companies. OrbiMed invests across various sectors within the healthcare industry, such as pharmaceuticals, life sciences, digital health, medical devices, biopharmaceuticals, diagnostics, healthcare technology, and biotechnology. With approximately $5 billion in assets under management, OrbiMed aims to support a spectrum of healthcare companies, from early-stage ventures to established multinational corporations.
Khosla Ventures, founded in 2004 and headquartered in Menlo Park, California, is a venture capital firm that provides strategic advice, capital, and support to bold entrepreneurs across various sectors. The firm focuses on early-stage investments in areas such as artificial intelligence, climate technology, sustainability, enterprise solutions, consumer products, fintech, digital health, medical technology, and therapeutics. Khosla Ventures is particularly interested in innovative solutions that address significant socio-economic challenges and enhance productivity, especially for low-income populations and small businesses in emerging markets. The firm embraces experimentation and is open to investing in unconventional and high-risk ventures, often acting as the sole investor in groundbreaking projects. With a commitment to fostering impactful entrepreneurship, Khosla Ventures seeks to create value through technological advancements and creative business models, with a special emphasis on markets in South Asia.
TEDCO is an independent organization established in 1998 and located in Columbia, Maryland. It serves as the leading source of entrepreneurial business assistance and seed funding for the development of startup companies within Maryland's innovation economy. TEDCO focuses on early-stage companies across various sectors, including software, technology, energy equipment, life sciences, and oncology. Its mission is to foster innovation and economic growth in Maryland by supporting the growth of startups and enhancing the state's position in the entrepreneurial landscape.
Johnson & Johnson Innovation - JJDC, established in 1973 and based in New Brunswick, New Jersey, serves as the corporate venture capital arm of Johnson & Johnson. The organization focuses on accelerating early-stage innovation by fostering strategic collaborations. JJDC connects potential partners with essential resources to support advancements in transformation science and technology across various sectors, including pharmaceuticals, medical devices, consumer healthcare, and medtech. Through its investment activities, JJDC aims to drive innovation and enhance the development of new solutions that can improve health and well-being.
The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise, entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Sofinnova Partners is a venture capital firm founded in 1972 and headquartered in Paris, France. The firm specializes in investing in the life sciences sector, focusing on biopharmaceuticals, biotechnology, medical devices, and industrial biotechnology. With over €2 billion in assets dedicated to life science investments, Sofinnova Partners partners with entrepreneurs at various stages, from seed to later-stage companies, including start-ups and corporate spin-offs. The firm actively seeks to take a lead role in financing, often becoming the first institutional investor in Series A rounds. It maintains an engaged presence in its portfolio companies by sitting on their boards and supporting them through to exit, thereby fostering transformative innovations that have the potential to make a significant positive impact on society.
New Enterprise Associates, Inc. is a private equity and venture capital firm founded in 1977 and headquartered in Menlo Park, California, with additional offices in India and China. The firm specializes in investing across various stages of business development, from seed funding to public offerings, with a strong emphasis on the technology and healthcare sectors. Its investment strategy encompasses a wide range of industries, including information technology, consumer internet, financial technology, software, healthcare services, life sciences, biopharmaceuticals, and energy technology. New Enterprise Associates actively engages with entrepreneurs to support the growth of their companies, making investments between $0.05 million and $20 million. The firm has a global investment focus, particularly in regions such as Asia, Brazil, and the United States.
Medtronic is a global leader in healthcare technology, specializing in solutions for complex and chronic conditions. The company develops a wide range of medical technologies that address 70 different medical conditions, including treatments for the lungs, brain, heart, diabetes, and women's health. Its product offerings encompass patient monitoring systems, robotic surgery, insulin pumps, and cardiac devices, among others. Medtronic is committed to improving patient outcomes through innovative therapies and technologies that provide lifelong solutions, particularly for those suffering from chronic pain. With a focus on addressing diverse healthcare challenges, Medtronic leverages its extensive knowledge and dedication to enhance the lives of patients worldwide.
Panakès Partners is a venture capital firm based in Milan, Italy, founded in 2015 by Fabrizio Landi, Alessio Beverina, and Diana Saraceni. The firm focuses on investing in early-stage startups and small to medium-sized enterprises within the life sciences sector across Europe and Israel. Panakès Partners seeks out ambitious companies and teams that are developing innovative technologies and products aimed at improving global health and quality of life. With a commitment to fostering revolutionary advancements in life sciences, the firm aims to support transformative solutions that address pressing health challenges.
CDP Venture Capital Sgr - National Innovation Fund aims to make venture capital a cornerstone of the country's economic development and innovation, creating the conditions for an overall and sustainable growth of the venture capital ecosystem.
IndieBio, founded in 2014 and based in San Francisco, is the world’s first accelerator dedicated to startups that leverage biology to address significant global challenges. As part of SOSV, a global venture capital firm, IndieBio focuses on nurturing seed-stage and early-stage companies across various sectors, including healthcare, life sciences, biotechnology, and consumer products. The accelerator provides funding and support to innovative ventures aiming to create impactful solutions in areas such as pharmaceuticals, oncology, and advanced manufacturing. By fostering emerging technologies and biological applications, IndieBio plays a crucial role in advancing the next generation of startups that seek to make a positive difference in society.
Enterprise Ireland is a government agency based in Dublin, Ireland, established in 1998 to foster the growth and development of indigenous businesses. Its primary mission is to assist Irish enterprises in achieving a strong presence in global markets, thereby enhancing national and regional prosperity. The agency supports a wide range of companies, from high-potential start-ups to established businesses, by providing funding, resources, and guidance. Additionally, Enterprise Ireland collaborates with college-based researchers to facilitate the development and commercialization of innovative technologies through licensing and spin-out companies. By focusing on innovation and export sales, Enterprise Ireland plays a crucial role in driving economic growth and competitiveness within the Irish economy.
Lumira Ventures is a venture capital firm that specializes in investing in emerging, mid, and late-stage companies within the healthcare and life sciences sectors. Founded in 2007 and headquartered in Toronto, Ontario, it has additional offices in Montreal, Vancouver, and Boston. The firm focuses on biotechnology, biopharmaceuticals, medical devices, digital health, and consumer health companies, primarily in North America, particularly Canada and the United States. Lumira Ventures typically invests between 5 million and 15 million in its portfolio companies, which currently includes over 30 active investees. The firm collaborates closely with management teams to enhance the value of their technology pipelines through strategic financing, board participation, and facilitating access to funding sources, partners, and market opportunities. With a history of over 100 investments since 1989, Lumira Ventures is recognized for its commitment to fostering innovation and addressing significant unmet needs in healthcare.
Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greater development space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services. Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns. Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise. By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Perceptive Advisors LLC is an investment management firm established in 1999, with headquarters in New York City and an additional office in Boston. The firm specializes in supporting the life sciences sector, investing primarily in biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services. Perceptive Advisors engages in venture capital and incubation, making equity investments ranging from $10 million to $200 million in both private and public companies. It manages client-focused equity portfolios and employs a long/short equity strategy as part of its hedging techniques. Additionally, the firm conducts in-house research and utilizes technical analysis to inform its investment decisions. Perceptive Advisors also provides customized debt financing solutions through its Perceptive Credit Opportunities Fund, catering to the evolving needs of healthcare companies.
The Bill & Melinda Gates Foundation is an independent non-profit organization based in Seattle, Washington, established in 2000. It is dedicated to reducing global inequities by focusing on improving health, alleviating extreme poverty, and supporting educational initiatives. The foundation also engages in community giving within the Pacific Northwest, promoting strategies and programs that assist low-income families. With regional offices in Washington, D.C.; New Delhi, India; Beijing, China; and London, United Kingdom, the foundation is governed by its co-founders, Bill and Melinda Gates, along with trustee Warren Buffett. Its mission encompasses a wide range of global challenges, aiming to create lasting change through targeted grant-making and programmatic efforts.
Sand Hill Angels is a collective of over 60 experienced Silicon Valley technology professionals that has been active since 2000. This group focuses on investing in early-stage and growth-stage technology startups across various sectors, including clean technology, Internet startups, information sciences, and life sciences. Their expertise encompasses areas such as semiconductors, enterprise software, storage, communications, medical devices, diagnostics, and bioinformatics. Sand Hill Angels typically invests between $300,000 and $500,000 in companies with pre-money valuations under $5 million, participating in seed or Series A rounds as well as later-stage bridge investments. The group's collaborative approach extends to working with venture capital funds and other angel organizations, contributing significantly to the Bay Area's technology startup ecosystem.
Novo Holdings is a Danish holding and investment firm based in Copenhagen, wholly owned by the Novo Nordisk Foundation. Established in 1999, it manages the Foundation's financial assets and aims to ensure sufficient dividends to support its grant obligations for medical and scientific research. Novo Holdings primarily invests in the life science sector, maintaining a diverse portfolio that includes equities, bonds, real estate, infrastructure, and private investments. It holds a significant ownership stake in Novo Nordisk A/S and Novozymes A/S, ensuring a material influence over these companies. The firm actively participates in their governance and is committed to supporting early-stage applied research in life sciences through initiatives like Novo Seeds. By investing in both early and later-stage life science companies, Novo Holdings seeks to balance financial risk while aiming for high returns, all within a framework of shared values and management principles across the Novo Group.
The European Investment Bank (EIB), established in 1958 and headquartered in Luxembourg, serves as the lending arm of the European Union, primarily focusing on supporting European integration and social cohesion. It offers a range of financial services, including project loans for both public and private sectors, loans to banks and intermediaries, and structured finance products. EIB also provides guarantees, securitization instruments, and equity investments, particularly in infrastructure and environmental projects. The bank plays a crucial role in financing microfinance and risk-sharing initiatives for research and innovation, alongside offering technical expertise for sustainable energy projects. Its advisory services encompass urban development and infrastructure, and it actively supports public-private partnerships and small to medium-sized enterprises across various sectors, including transportation, energy, health, education, and agriculture.
Lilly Asia Ventures, established in 2008 and based in Shanghai, China, serves as the corporate venture capital arm of Eli Lilly and Company. The firm focuses on making investments in promising life science companies that exhibit strong management teams and innovative technologies or business models. While its primary investment strategy targets opportunities in China, Lilly Asia Ventures is also open to exploring prospects in other regions of East and South Asia. The firm invests across various stages, including seed, early, and later stages, with particular interest in sectors such as healthcare, life sciences, oncology, manufacturing, and technology-based industries. Through its investments, Lilly Asia Ventures aims to foster the development of innovative solutions that contribute to improved health and quality of life.
Lightstone Ventures is a venture capital firm established in 2012 and headquartered in Menlo Park, California, with additional offices in Boston, Dublin, and Singapore. The firm specializes in investing in early-stage and late-stage companies within the healthcare and life sciences sectors, focusing on personalized medicines, targeted therapeutics, medical devices, and novel biopharmaceuticals. By targeting innovative startups primarily in Europe and Australia, Lightstone Ventures aims to capitalize on advancements in life sciences and the unique opportunities within the industry. The firm is recognized as a Registered Investment Adviser, emphasizing its commitment to strategic investments in breakthrough technologies that can transform healthcare.
Hatteras Venture Partners is a venture capital firm based in Durham, North Carolina, founded in 2000. The firm specializes in investing in early-stage and emerging growth companies, primarily within the life sciences and healthcare sectors. Its investment focus includes biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related technologies that enhance human health. Hatteras Venture Partners aims to support companies located in research-driven and capital-underserved regions, particularly in the Mid Atlantic and Southeastern United States. The firm typically makes initial investments ranging from $0.5 million to $4 million, with total investments reaching between $5 million and $20 million. The team at Hatteras Venture Partners possesses extensive operational experience and a successful track record, enabling them to effectively enhance the value of their portfolio companies.
Legend Capital, established in 2001 and based in Beijing, China, is a prominent venture capital firm and a subsidiary of Legend Holdings Ltd. The firm focuses on investing in high-growth ventures primarily within China or related markets, managing approximately US$700 million across multiple funds. Legend Capital emphasizes early-stage investments in the information technology sector, particularly in network applications and services, as well as in infrastructure and professional services. Additionally, it targets mid-market growth companies in consumer goods, clean technology, healthcare, equipment manufacturing, and modern services. With a portfolio of over 60 companies, Legend Capital actively supports its investments by providing extensive business resources and tailored services, aimed at enhancing business development and brand building in the Chinese market.
Zürcher Kantonalbank is an independent, incorporated public-law institution is its public service mandate. Enshrined in law, it governs the bank's economic, social, and environmental commitment.
ShangBay Capital is a venture capital firm established in 2015 and located in Palo Alto, California. The firm specializes in investing in the life sciences sector, with a particular focus on medical devices, biotechnology, and mobile healthcare companies within the United States. As a Registered Investment Adviser, ShangBay Capital seeks to support innovative early-stage companies that are poised to make significant advancements in healthcare technology.
Korea Investment Partners is a prominent venture capital and private equity firm based in Seoul, South Korea, with over 30 years of experience in the investment sector. Founded in 1986, the firm focuses on supporting bold and innovative entrepreneurs across various industries, including biotechnology, healthcare, interactive content, media, consumer internet, financial technology, information and communication technology, digitalization, semiconductor, and industrial sectors. Korea Investment Partners has established a strong track record by investing in notable companies such as Kakao, Naver, YG Entertainment, Bodyfriend, and Didi Chuxing. The firm manages more than 20 venture and private equity funds, with total assets under management amounting to approximately $1.8 billion. In addition to its headquarters in Seoul, Korea Investment Partners has offices in Shanghai, Beijing, and Sunnyvale, allowing it to operate on a global scale.
Versant Ventures is a healthcare investment firm founded in 1999 and based in San Francisco, California. It focuses on supporting exceptional entrepreneurs in building innovative companies across various sectors within healthcare, including biotechnology, life sciences, pharmaceuticals, and oncology. With $2.3 billion under management, the firm invests at all stages of company development, emphasizing the discovery and development of novel therapeutics. Versant’s team possesses extensive investment, operational, and scientific expertise, allowing for a hands-on approach to company building. Since its inception, more than 65 companies associated with Versant have successfully achieved acquisitions or initial public offerings, reflecting the firm’s commitment to fostering growth in the healthcare industry.
For more than 20 years, Innovation Works has played a vital role in Southwestern PA's technology economy, investing capital, business expertise, and other resources into high-potential companies with the greatest likelihood for regional economic impact. IW is the single largest investor in seed-stage companies in the region. They also provide resources for manufacturers to adopt new technologies.
Vivo Capital is a global investment firm established in 1996 and headquartered in Palo Alto, California, with additional offices in Asia. With approximately $5.8 billion in assets under management, Vivo has invested in over 290 public and private companies, primarily within the healthcare sector. The firm employs a team of 50 professionals who possess diverse expertise, including physicians, scientists, entrepreneurs, and industry executives. Vivo Capital operates as a multi-fund investment platform, engaging in strategies that encompass growth equity, private equity, venture capital, and public equity. Its investment focus spans various healthcare subsectors, including biopharmaceuticals, specialty pharmaceuticals, medical devices, and healthcare services, with an emphasis on significant healthcare markets in the United States and East Asia.
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.
Alumni Ventures Group, LLC is a venture capital firm based in Manchester, New Hampshire, founded in 2013. The firm specializes in seed and early-stage investments, as well as late-stage pre-IPO opportunities, with a flexible approach that is sector and geographic agnostic. Alumni Ventures aims to provide high-quality, diversified venture portfolios to individual investors, particularly accredited alumni from top entrepreneurial schools, who may not have had access to venture capital previously. The firm focuses on backing companies that have an alumni connection and are led by established institutional investors with expertise in their respective fields. Additionally, Alumni Ventures offers focused funds that enable accredited investors to access a diverse portfolio of investments across various types, sectors, stages, and geographies.
UI Investissement, formerly known as UI Gestion SAS, is a private equity and venture capital firm established in 2004 and headquartered in Paris, France. The firm specializes in investments in small to mid-cap companies across various sectors, with a particular focus on healthcare, agri-food, and services industries. Over the years, UI Investissement has actively supported the growth of more than 120 small and medium-sized enterprises, investing over €550 million in their development projects. The firm aims to finance a wide range of business stages, including seed, startup, and growth capital, as well as buyouts and turnaround transactions. Its investment strategy is regionally focused, primarily targeting areas in France such as Aquitaine, Brittany, and Ile-de-France, and it typically invests between €1 million and €50 million depending on the enterprise value of the companies. UI Investissement aims to act as both a majority and minority shareholder, leveraging its experience and corporate culture to foster sustainable performance in its portfolio companies.
Kohlberg Kravis Roberts is a prominent global investment firm that specializes in managing a diverse range of alternative asset classes, including private equity, energy, infrastructure, real estate, and credit, as well as hedge funds through strategic partnerships. Founded in 1976, the firm focuses on generating attractive investment returns by employing a disciplined and patient investment approach. KKR is committed to driving growth and value creation in its portfolio companies while aligning its interests with those of its investment partners. The firm also provides comprehensive human resources services to enhance operational effectiveness. With a presence in multiple countries, including India and Japan, KKR continues to leverage its extensive expertise and industry knowledge to deliver value across its investment strategies.
Sunland Fund is a venture capital firm established in 2014 and headquartered in Shanghai, China. The firm specializes in investing in early and growth-stage companies within the medical and healthcare sectors. Its focus areas include biomedicine, medical devices such as in vitro diagnostics and genetic technology, minimally invasive interventions, implantable devices, surgical instruments, medical robots, and healthcare services. Sunland Fund seeks to support high-growth segments in the healthcare industry, leveraging a team with expertise in financial and strategic investment, as well as experience in the medical industry.
Insight Partners is a global software investor that partners with growth-stage technology and software companies. Insight has a deep focus in Fintech, Cybersecurity, AI/ML, DevOps, and Healthcare sectors. Across their people and their portfolio, they encourage a culture around a core belief growth equals opportunity. As of December 31, 2022, the firm has over $75B in regulatory assets under management. Insight Partners has invested in more than 750 companies worldwide and has seen over 55 portfolio companies achieve an IPO.
Temasek Holdings is a Singapore-based investment company founded in 1974. The firm specializes in providing debt financing and is dedicated to transforming economies, enhancing middle-income populations, and fostering emerging champions. Temasek operates across various sectors, including financial services, transportation, industrial, consumer goods, real estate, telecommunications, media, technology, and life sciences. Its strategic focus is on developing comparative advantages within these industries to support sustainable growth and innovation.